We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone Device Created Performs Blood Tests

By LabMedica International staff writers
Posted on 03 Apr 2014
A smartphone device has been created that can perform blood tests—an innovation that could improve the quality of life for people undergoing treatment for the prevention of blood clots.

The formation of blood clots in the arteries and veins can increase the risk of heart attack and stroke, and individuals at high risk of blood clots are often treated with anticoagulants drugs that thin the blood and prevent the clotting process.

Bioengineers at the École Polytechnique Fédérale de Lausanne (EPFL; Switzerland) microengineering laboratory have created a device that could allow patients undergoing anticoagulant therapy to self-monitor. More...
The gadget consists of a small single-use film that is attached to the screen of a smartphone. The film is made of a microstructured plastic layer that is a few micrometers thick.

When blood enters the film through capillary action, the device can detect a molecule present in blood that initiates coagulation, the process by which blood forms clots. The phone is then able to interpret the results by analyzing interferences in the electric field on the surface of the smartphone's screen. This is a process similar to what happens when a finger comes into contact with the screen of a smartphone. The results are then sent to a specific smartphone application, created by Qloudlab (Lausanne, Switzerland), the start-up company based at EPFL. This data can then be sent directly to a physician, who can assess whether a patient’s treatment needs to be modified.

Qloudlab has recently applied for a patent for the device, and the creators have recently received funding from Venture Kick (St. Gallen, Switzerland) that has allowed them to recruit a biochemist. The team hopes that by the end of next year, they will have shown that the device is as reliable as a laboratory test and can progress toward commercialization. Arther Queval, MSc, the founder of Qloudlab, said, “Such a test will significantly improve the quality of life for people undergoing this kind of treatment."

Related Links:

École Polytechnique Fédérale de Lausanne
Qloudlab 
Venture Kick



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Portable POCT Blood Gas Analyzer
BD100
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.